Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 2/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.30 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6899147 | 0.97 | CTSB (0.34) | ALDH1A1SIGMAR1KDM4EHSD11B1LMNA | |
| SCHEMBL6895838 | 0.87 | SIGMAR1 (0.31) | ALDH1A1SIGMAR1KDM4EHSD11B1LMNA | |
| SCHEMBL6891136 | 0.84 | CTSB (0.32) | ALDH1A1SIGMAR1KDM4ELMNATSHR | |
| SCHEMBL6897865 | 0.80 | CASR (0.36) | ALDH1A1SIGMAR1LMNATP53CTSL | |
| SCHEMBL6898335 | 0.78 | CNR1 (0.36) | ALDH1A1SIGMAR1KDM4EHSD11B1LMNA | |
| SCHEMBL6895192 | 0.77 | CNR2 (0.38) | ALDH1A1LMNATP53CTSLCTSB | |
| SCHEMBL7213998 | 0.75 | SIGMAR1 (0.46) | ALDH1A1SIGMAR1HSD11B1TSHRCNR1 | |
| SCHEMBL7213852 | 0.75 | KMT2A (0.39) | SIGMAR1KDM4E | |
| SCHEMBL7220859 | 0.71 | SIGMAR1 (0.36) | SIGMAR1KDM4E | |
| SCHEMBL7220863 | 0.71 | SIGMAR1 (0.36) | SIGMAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| CN-1299344-A | Novel urea derivatives | SANTEN PHARCEUMATICAL CO LTD (JP) | 2001-06-13 | — | — | CN | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | ALDH1A1 1309/4885SIGMAR1 26/4885KDM4E 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.